RNXT4:05 PMRenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue GrowthEnrollment • Phase 3Enrollment milestone Wed, Aug 12, 2026, 4:05 PM EDTGrenovorx.com
RNXT8:30 AMRenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic CancerEnrollment • Phase 3Enrollment completion Fri, Aug 7, 2026, 8:30 AM EDTGrenovorx.com
RNXT8:30 AMRenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumorsrenovorx.com
RNXT8:30 AMRenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13threnovorx.com
RNXT8:30 AMRenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ETrenovorx.com
RNXT8:30 AMRenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancerrenovorx.com
RNXT8:30 AMRenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rdEnrollment • Phase 3Enrollment completion Tue, Jun 30, 2026renovorx.com
RNXT8:30 AMRenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancerrenovorx.com
RNXT8:30 AMRenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual MeetingPresentation / Abstract • Phase 3ASCO abstract release Thu, May 21, 2026, 5:00 PM ETGrenovorx.com
RNXT8:30 AMRenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20thEnrollment • Phase 3Enrollment completion Tue, Jun 30, 2026renovorx.com